- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03677986
Buprenorphine Treatment Engagement and Overdose Prevention
July 24, 2023 updated by: Johns Hopkins University
Buprenorphine Treatment Engagement and Overdose Prevention in Opioid Users
Office-based buprenorphine could be expanded to treat many of the opioid users who are not in treatment and who are at great risk for opioid overdose, but effective approaches are needed to help individuals with opioid use disorder initiate and remain in office-based buprenorphine treatment.
Investigators propose to develop and pilot test a novel intervention that will combine video-based directly observed therapy and incentives to promote buprenorphine treatment engagement and adherence in out-of-treatment opioid users.
Study Overview
Detailed Description
The United States is experiencing an epidemic of opioid-related overdose deaths.
Office-based buprenorphine treatment could expand access to treatment to the many opioid users who are not in treatment and who are at great risk for opioid overdose.
However, office-based buprenorphine has two limitations that Investigators will address in this application: 1) Patients prescribed buprenorphine by office-based providers can divert the buprenorphine for illicit use.
2) Many people in need of buprenorphine treatment do not initiate and remain in office-based buprenorphine treatment.
Investigators will use Video Directly Observed Therapy (DOT) and incentives to enhance office-based buprenorphine treatment.
Video DOT is an innovative, mobile health platform that patients can use to record and submit videos of patients taking medication that are then viewable on a secure, web portal for providers to confirm medication adherence.
Video DOT could facilitate adherence to buprenorphine treatment and safeguard against diversion.
The addition of incentives could engage out-of-treatment opioid users into treatment and increase treatment retention.
Incentive interventions, which provide incentives to patients meeting therapeutic goals, have been highly effective in promoting a wide range of health behaviors and have firm theoretical and empirical foundations.
Incentive interventions can promote treatment engagement in individuals with substance use disorders, including out-of-treatment opioid users.
Investigators propose to develop and pilot test a novel combination of Video DOT and incentives to promote buprenorphine treatment engagement and adherence in out-of-treatment opioid users.
The Video DOT+ intervention will provide an incentive for linking to buprenorphine treatment and facilitate retention in treatment by providing incentives for maintaining daily buprenorphine use as verified by the Video DOT system.
The incentives will be integrated into the Video DOT platform and delivered remotely to reloadable credit cards to allow for the entire intervention to be delivered via mobile technology and to facilitate easy dissemination of the Video DOT+ system.
A randomized pilot study is planned over 3 years.
Out-of-treatment opioid users (N=64) will be referred to buprenorphine treatment and randomly assigned to a Usual Care (Control) group or Video DOT+ group.
Video DOT+ participants will receive the Video DOT+ intervention being developed and evaluated in this project.
Investigators will assess participants every 4 weeks throughout a 24-week intervention period and at 12 weeks after the intervention ends.
The primary outcome measure will be buprenorphine treatment adherence during the 24-week intervention.
Secondary measures will include buprenorphine treatment engagement (linkage and retention), opioid use, risk of opioid overdose, and post-intervention effects.
The project will allow for the development and preliminary evaluation of a novel intervention to promote buprenorphine treatment engagement and adherence in out-of-treatment opioid users.
Ultimately, Investigators would like to develop and disseminate an effective and scalable intervention that can enhance office-based buprenorphine treatment and thereby combat the opioid overdose epidemic.
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kenneth Silverman, Ph.D.
- Phone Number: 410-550-2694
- Email: ksilverm@jhmi.edu
Study Contact Backup
- Name: Jackie Hampton
- Phone Number: 1-866-857-9851
- Email: jhampton@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Center for Learning and Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- opioid use disorder
Exclusion Criteria:
- current suicidal/homicidal ideation
- severe psychiatric disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual Care
Participants in this group will be referred to receive office-based buprenorphine treatment
|
|
Experimental: Video DOT+
Participants in this group will be referred to receive office-based buprenorphine treatment and will receive financial incentives for taking their daily buprenorphine dose.
|
Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Buprenorphine Treatment Adherence
Time Frame: 24 weeks
|
This will be assessed by the percentage of buprenorphine-positive urine samples during the 24-week intervention.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Linkage to Treatment
Time Frame: 24 weeks
|
This will be assessed by the percentage of participants who get linked to buprenorphine treatment during the 24-week intervention
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kenneth Silverman, Ph.D., Johns Hopkins School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2019
Primary Completion (Actual)
July 28, 2020
Study Completion (Actual)
October 20, 2020
Study Registration Dates
First Submitted
September 18, 2018
First Submitted That Met QC Criteria
September 18, 2018
First Posted (Actual)
September 19, 2018
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
July 24, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00186156
- R01CE003069-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-use Disorder
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorder | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Hennepin Healthcare Research InstituteNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCRecruitingSubstance Use Disorders | Opioid Use Disorder, Moderate | Opioid Use Disorder, SevereUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Vanderbilt University Medical CenterCompletedOpioid Use | Opioid-use DisorderUnited States
-
Albert Einstein College of MedicineNational Institute on Drug Abuse (NIDA); Pfizer; National Institutes of Health...Active, not recruitingTobacco Use Disorder | Opioid-use DisorderUnited States
-
Indiana UniversityCompletedOpioid Use | Opioid-use DisorderUnited States
-
Brigham and Women's HospitalOhio State UniversityActive, not recruitingOpioid Dependence | Opioid Use | Opioid-use DisorderUnited States
-
New York State Psychiatric InstituteColumbia University; Weill Medical College of Cornell University; National Institute... and other collaboratorsActive, not recruitingOpioid Use | Opioid Court Model | Medication to Treat Opioid Use DisorderUnited States
-
University of ZurichCompletedOpioid Use, Unspecified With Other Opioid-induced DisorderSwitzerland
Clinical Trials on Video DOT+
-
Centers for Disease Control and PreventionColumbia University; New York City Department of Health and Mental HygieneCompletedTuberculosis | Adherence, Medication | Drug-resistant Tuberculosis | Adherence, PatientUnited States
-
University of GeorgiaMakerere UniversityCompleted
-
University of WashingtonNational Institute on Drug Abuse (NIDA); emocha Mobile Health, Inc.CompletedOpioid-Related DisordersUnited States
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of California, San DiegoCompletedTuberculosis | Latent Tuberculosis InfectionUnited States
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI); emocha Mobile Health, Inc.Not yet recruitingPatient Engagement | Health Behavior | Immune Suppression | Heart Transplant Rejection | Medication Nonadherence | Remote Monitoring | Pediatric Heart TransplantUnited States
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Environment and Health Group, Inc.Completed
-
SightGlass Vision, Inc.University of WaterlooCompletedMyopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in ContrastCanada
-
Oslo University HospitalCompleted